Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 1, 2006, Pages 418-423

  Hale, Sharon L ^a   Leeka, Justin A ^a   Kloner, Robert A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BOLUS INJECTION; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HEART RATE; HEART STROKE VOLUME; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY;

ANIMALS; MALE; MYOCARDIAL REPERFUSION INJURY; NECROSIS; PIPERAZINES; RABBITS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; VENTRICULAR FUNCTION, LEFT;

EID: 33745266444     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.103242     Document Type: Article

References (29)

1. Allely MC and Alps BJ (1990) Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol 99:5-6.
2. American Heart Association (1985) Position of the American Heart Association on research animal use. Circulation 71:849A.
3. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, and Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110:904-910.
4. Belardinelli L, Antzelevitch C, and Fraser H (2004) Inhibition of late (sustained/persistent) sodium channel: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 6 (Suppl 1):13-17.
5. Belardinelli L, Shryock JC, and Fraser H (2006) The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J 8 (Suppl A):A10-A13.
6. + regulation in cardiac myocytes. Cardiovasc Res 57:871-872.
7. Black SC, Gralinski MR, McCormack JG, Driscoll EM, and Lucchesi BR (1994) Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion. J Cardiovasc Pharmacol 24:921-928.
8. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, and Wolff AA; Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators (2004a) Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. A randomized controlled trial. J Am Med Assoc 291:309-316.
9. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Herbert DA, et al. (for the MARISA Investigators) (2004b) Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 43:1375-1382.
10. Clarke B, Spedding M, Patmore L, and McCormack JG (1993) Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in pyruvate dehydrogenase. Br J Pharmacol 109:748-750.
11. Fredj S, Sampson KJ, Liu H, and Kass RS (2006) Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol, in press.
12. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, and Lucchesi BR (1994) Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res 28:1231-1237.
13. Hale SL and Kloner RA (1998) Myocardial temperature reduction attenuates necrosis after prolonged ischemia in rabbits. Cardiovasc Res 40:502-507.
14. + exchange inhibition on infarct size in rabbits. Am J Physiol 279:H2673-H2677.
15. Imahashi K, Kusuoka H, Hashimoto K, Yoshioka J, Yamaguchi H, and Nishimura T (1999) Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res 84:1401-1406.
16. Jain D, Dasgupta P, Hughes LO, Lahiri A, and Raftery EB (1990) Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischaemic myocardium. Eur J Clin Pharmacol 38:111-114.
17. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, and Karran EH (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:26-32.
18. McCormack JG, Barr RL, Wolff AA, and Lopaschuk GD (1996) Ranolazine stimulates glucose oxidation in normoxic, ischemic and reperfused ischemic rat hearts. Circulation 93:135-142.
19. Murphy E, Cross H, and Steenbergen C (1999) Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res 84:1469-1470.
20. Pepine CJ and Wolffe AA; on behalf of the Ranolazine group (1999) A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 84:46-50.
21. Rousseau MF, Pouleur H, Cocco G, and Wolff AA (2005) Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 95:311-316.
22. NA in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44:192-199.
23. Thadani U, Ezekowitz M, Fenney L, and Chiang Y-K; for the Ranolazine group (1994) Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina. Circulation 90:726-734.
24. Undrovinas A, Belardinelli L, Undrovinas N, and Sabbah H (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17 (Suppl 1):S1-S9.
25. Undrovinas AI, Fleidervish IA, and Makielski JC (1992) Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 71:1231-1241.
26. Ward CA and Giles WR (1997) Ionic mechanism of the effects of hydrogen peroxide in rat ventricular myocytes. J Physiol (Lond) 500:631-642.
27. Wu J and Corr PB (1994) Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am J Physiol 266:H1034-H1046.
28. + exchanger during ischemia and preconditioning in the isolated rat heart. Circ Res 85:723-730.
29. Zacharowski K, Blackburn B, and Thiemermann C (2001) Ranolazine, a partial fatty acid oxidation inhibitor, reduced myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol 418:105-110.